Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.67 |
| ▸ | CCR2 | P41597 | 15/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1762485 | 0.93 | CYP2C9 (0.68) | CYP2C9CYP3A4CCR2 | |
| SCHEMBL306072 | 0.92 | CYP2C9 (0.65) | CYP2C9CYP3A4CCR2KCNH2 | |
| SCHEMBL1762385 | 0.92 | CYP3A4 (0.79) | CYP2C9CYP3A4CCR2TSHR | |
| SCHEMBL22461660 | 0.92 | CYP2C9 (0.65) | CYP2C9CYP3A4CCR2TSHR | |
| SCHEMBL1762415 | 0.92 | CYP2C9 (0.65) | CYP2C9CYP3A4CCR2 | |
| SCHEMBL12648721 | 0.92 | CYP2C9 (0.70) | CYP2C9CYP3A4CCR2TSHRKCNH2 | |
| SCHEMBL1762449 | 0.91 | CYP2C9 (0.64) | CYP2C9CYP3A4CCR2 | |
| SCHEMBL1762442 | 0.90 | CYP2C9 (0.64) | CYP2C9CYP3A4CCR2KCNH2 | |
| SCHEMBL1762350 | 0.90 | CYP2C9 (0.63) | CYP2C9CYP3A4CCR2KCNH2 | |
| SCHEMBL1762514 | 0.89 | CYP2C9 (0.61) | CYP2C9CYP3A4CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3463350-B1 | PYRROLO-PYRIDINES AND PYRROLO-PYRIMIDINES FOR USE IN TREATING LIVER FIBROSIS | CHEMOCENTRYX INC (US) | 2023-09-13 | — | — | EP | disclosed |
| EP-4134080-A1 | CCR2 INHIBITORS FOR USE IN TREATING RENAL DISEASES | ChemoCentryx, Inc. (US) | 2023-02-15 | — | — | EP | disclosed |
| US-11433061-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. (US) | 2022-09-06 | — | — | US | disclosed |
| US-11433061-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. (US) | 2022-09-06 | — | — | US | disclosed |
| US-11357760-B2 | Method of treating liver fibrosis | CHEMOCENTRYX, INC. (US) | 2022-06-14 | — | — | US | disclosed |
| US-11324736-B2 | Method of Treating Focal Segmental Glomerulosclerosis | CHEMOCENTRYX, INC. (US) | 2022-05-10 | — | — | US | disclosed |
| US-20210401816-A1 | METHODS OF TREATING PANCREATIC CANCER | CHEMOCENTRYX, INC. | 2021-12-30 | — | — | US | disclosed |
| US-11116756-B2 | Methods of treating pancreatic cancer | CHEMOCENTRYX, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| EP-3468548-B1 | METHODS OF TREATING PANCREATIC CANCER | CHEMOCENTRYX INC (US) | 2021-08-04 | — | — | EP | disclosed |
| US-10973809-B2 | Method of treating focal segmental glomerulosclerosis | CHEMOCENTRYX, INC. (US) | 2021-04-13 | — | — | US | disclosed |
| US-20100056509-A1 | HETEROARYL SULFONAMIDES AND CCR2 | CHEMOCENTRYX, INC. | 2010-03-04 | — | — | US | disclosed |
| US-20100056509-A1 | HETEROARYL SULFONAMIDES AND CCR2 | CHEMOCENTRYX, INC. | 2010-03-04 | — | — | US | disclosed |
| US-20100056509-A1 | HETEROARYL SULFONAMIDES AND CCR2 | CHEMOCENTRYX, INC. | 2010-03-04 | — | — | US | disclosed |
| US-7622583-B2 | Heteroaryl sulfonamides and CCR2 | CHEMOCENTRYX, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-7622583-B2 | Heteroaryl sulfonamides and CCR2 | CHEMOCENTRYX, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-7622583-B2 | Heteroaryl sulfonamides and CCR2 | CHEMOCENTRYX, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| WO-2008008431-A2 | HETEROARYL SULFONAMIDES AND CCR2/CCR9 | CHEMOCENTRYX, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
| US-20070037794-A1 | 4-((5-Chloro-3-(4-methyl-3-trifluoromethylbenzenesulfonylamino)pyridin-2-yl)-oxo-)1H-pyrrolo(2,3-)pyridine;interfere with ligand (monocyte chemoatactic protein-1) for chemokine receptors (CCR2); antiinflammatory agents; immunomodulators; bactericides; viricides; fungicides | CHEMOCENTRYX, INC. | 2007-02-15 | — | — | US | disclosed |
| US-20070037794-A1 | 4-((5-Chloro-3-(4-methyl-3-trifluoromethylbenzenesulfonylamino)pyridin-2-yl)-oxo-)1H-pyrrolo(2,3-)pyridine;interfere with ligand (monocyte chemoatactic protein-1) for chemokine receptors (CCR2); antiinflammatory agents; immunomodulators; bactericides; viricides; fungicides | CHEMOCENTRYX, INC. | 2007-02-15 | — | — | US | disclosed |
| US-20070037794-A1 | 4-((5-Chloro-3-(4-methyl-3-trifluoromethylbenzenesulfonylamino)pyridin-2-yl)-oxo-)1H-pyrrolo(2,3-)pyridine;interfere with ligand (monocyte chemoatactic protein-1) for chemokine receptors (CCR2); antiinflammatory agents; immunomodulators; bactericides; viricides; fungicides | CHEMOCENTRYX, INC. | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11433061-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CCR2, CCR9, CCR1 | CYP2C9 192/4885CYP3A4 1934/4885CCR2 1/4885 |
| US-11116756-B2 | Methods of treating pancreatic cancer | RNASE1, KRAS, PNLIP | CYP2C9 4885/4885CYP3A4 4881/4885CCR2 3698/4885 |
| US-20210401816-A1 | METHODS OF TREATING PANCREATIC CANCER | RNASE1, KRAS, PNLIP | CYP2C9 4885/4885CYP3A4 4881/4885CCR2 3698/4885 |
| US-20070037794-A1 | 4-((5-Chloro-3-(4-methyl-3-trifluoromethylbenzenesulfonylamino)pyridin-2-yl)-oxo-)1H-pyrrolo(2,3-)pyridine;interfere with ligand (monocyte chemoatactic protein-1) for chemokine receptors (CCR2); antiinflammatory agents; immunomodulators; bactericides; viricides; fungicides | CCR2, CCR1, CCL2 | CYP2C9 1187/4885CYP3A4 1108/4885CCR2 1/4885 |
| US-20100056509-A1 | HETEROARYL SULFONAMIDES AND CCR2 | CCR2, CXCR2, CCR1 | CYP2C9 1137/4885CYP3A4 1214/4885CCR2 1/4885 |
| US-10973809-B2 | Method of treating focal segmental glomerulosclerosis | SLC5A1, PTGFR, HPGDS | CYP2C9 2646/4885CYP3A4 3325/4885CCR2 610/4885 |
| US-11324736-B2 | Method of Treating Focal Segmental Glomerulosclerosis | SLC5A1, PTGFR, HPGDS | CYP2C9 2646/4885CYP3A4 3325/4885CCR2 610/4885 |
| US-11357760-B2 | Method of treating liver fibrosis | CCR2, CMKLR2, CCL2 | CYP2C9 1921/4885CYP3A4 1173/4885CCR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.